Daniel Lochner

Director of Finance/CFO at OYSR POIN

42 year

Consumer Services

Finance

Health Technology

Profile

Daniel Lochner is currently the Chief Financial & Business Officer at Oyster Point Pharma, Inc. He previously worked as a Portfolio Manager at Goldman Sachs Asset Management LP from 2005 to 2019.
Mr. Lochner holds an MBA from The Trustees of Columbia University in The City of New York and an undergraduate degree from the University of Richmond.

Daniel Lochner active positions

Companies	Position	Start
OYSR POIN	Director of Finance/CFO	01/07/2019

All active positions of Daniel Lochner

Former positions of Daniel Lochner

Companies	Position	End
Goldman Sachs Asset Management LP Goldman Sachs Asset Management LP Investment ManagersFinance Goldman Sachs Asset Management LP (GSAMLP) is a SEC-registered investment advisor headquartered in New York City. The firm is a wholly owned subsidiary of GSAM Holdings LLC, and their ultimate parent is Goldman Sachs Group, Inc. (NYSE: GS). Founded in 1988, GSAMLP provides investment solutions to a range of individual and institutional investors worldwide.	Portfolio Manager-Equities	01/07/2019

See the detail of Daniel Lochner's experience

Training of Daniel Lochner

The Trustees of Columbia University in The City of New York	Masters Business Admin
University of Richmond	Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Daniel Lochner's experience

Connections

100 +

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
Goldman Sachs Asset Management LP Goldman Sachs Asset Management LP Investment ManagersFinance Goldman Sachs Asset Management LP (GSAMLP) is a SEC-registered investment advisor headquartered in New York City. The firm is a wholly owned subsidiary of GSAM Holdings LLC, and their ultimate parent is Goldman Sachs Group, Inc. (NYSE: GS). Founded in 1988, GSAMLP provides investment solutions to a range of individual and institutional investors worldwide.	Finance
Oyster Point Pharma, Inc. Oyster Point Pharma, Inc. Pharmaceuticals: MajorHealth Technology Oyster Point Pharma, Inc. engages in the development and commercialization of pharmaceutical therapies to treat ocular surface diseases. Its product candidate, OC-01, is a nicotinic acetylcholine receptor agonist, which is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. The company was founded by Michael and is Ackermann in June 30, 2015 headquartered in Princeton, NJ.	Health Technology